Herriot Tabuteau Sells 4,660 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 4,660 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the completion of the sale, the chief executive officer owned 7,229 shares in the company, valued at $1,546,644.55. The trade was a 39.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Herriot Tabuteau also recently made the following trade(s):

• On Wednesday, August 5th, Herriot Tabuteau sold 45,004 shares of Axsome Therapeutics stock. The stock was sold at an average price of $212.01, for a total transaction of $9,541,298.04.
• On Wednesday, July 1st, Herriot Tabuteau sold 49,666 shares of Axsome Therapeutics stock. The stock was sold at an average price of $240.25, for a total transaction of $11,932,256.50.
• On Tuesday, June 9th, Herriot Tabuteau sold 49,670 shares of Axsome Therapeutics stock. The shares were sold at an average price of $241.01, for a total value of $11,970,966.70.

Axsome Therapeutics Stock Up 1.2%

Axsome Therapeutics stock opened at $212.74 on Friday. Axsome Therapeutics, Inc. has a 1-year low of $102.67 and a 1-year high of $260.19. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32. The stock has a market cap of $10.95 billion, a PE ratio of -57.03 and a beta of 0.65. The stock’s fifty day moving average is $236.95 and its two-hundred day moving average is $203.96.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AXSM shares. Guggenheim boosted their target price on Axsome Therapeutics from $245.00 to $260.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. Deutsche Bank Aktiengesellschaft set a $280.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, May 5th. Wells Fargo & Company boosted their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Cantor Fitzgerald restated an “overweight” rating and set a $272.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $265.55.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AXSM. Franklin Street Advisors Inc. NC purchased a new stake in Axsome Therapeutics in the 4th quarter valued at $1,826,000. Pictet Asset Management Holding SA grew its position in Axsome Therapeutics by 20.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company’s stock worth $79,643,000 after purchasing an additional 73,925 shares during the last quarter. Norges Bank purchased a new position in Axsome Therapeutics during the 4th quarter worth $90,490,000. Axiom Investors LLC DE increased its stake in Axsome Therapeutics by 28.7% in the fourth quarter. Axiom Investors LLC DE now owns 63,390 shares of the company’s stock valued at $11,578,000 after purchasing an additional 14,137 shares during the period. Finally, M&T Bank Corp increased its stake in Axsome Therapeutics by 2,553.8% in the fourth quarter. M&T Bank Corp now owns 49,466 shares of the company’s stock valued at $8,277,000 after purchasing an additional 47,602 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.